Claims for Patent: RE40667

Summary for Patent: RE40667

Title:	[R-(R*R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl-3-- phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
Abstract:	[R-(R*,R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-((1-methylethyl)- -3-phenyl-4-[(phenylamino)-carbonyl)]-1H-pyrrole-1-heptanoic acid or (2R-trans)-5-(4-fluoro-phenyl)-2-(1-methylethyl-N,4-diphenyl-1-[2-(tetrah- ydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide; and pharmaceutically acceptable salts thereof.
Inventor(s):	Roth; Bruce (San Jose, CA)
Assignee:	Warner-Lambert Company LLC (New York, NY)
Application Number:	11/653,830
Patent Claims:	1. [R-(R*,R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methyl- ethyl)-3-phenyl-4-[(phenylamino)-carbonyl]-1H-pyrrole-1-heptanoic acid or (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrah- ydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide; or pharmaceutically acceptable salts thereof..]. .[.2. A compound of claim 1 which is [R-(R*R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid..]. .[.3. A compound of claim 1 which is (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrah- ydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide..]. .[.4. The monosodium salt of the compound of claim 2..]. .[.5. The monopotassium salt of the compound of claim 2..]. 6. The hemicalcium salt of .[.the compound of claim 2.]. .Iadd.[R-(R*,R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methyl- ethyl)-3-phenyl-4-[(phenylamino)-carbonyl]-1H-pyrrole-1-heptanoic acid.Iaddend.. .[.7. The N-methylglucamine salt of the compound of claim 2..]. .[.8. The hemimagnesium salt of the compound of claim 2..]. .[.9. The hemizinc salt of the compound of claim 2..]. .[.10. The 1-deoxy-1-(methylamino)-D-glucitol mixture with the compound of claim 2..]. .[.11. A pharmaceutical composition for treating hypercholesterolemia comprising a hypocholesterolemic effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier..]. .[.12. A method of inhibiting cholesterol synthesis in a human suffering from hypercholesterolemia comprising administering a compound of claim 1 in unit dosage form..]. .Iadd.13. A pharmaceutical composition for treating hypercholesterolemia comprising a hypocholesterolemic effective amount of the hemicalcium salt of [R-(R*,R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methyleth- yl)-3-phenyl-4-[(phenylamino)-carbonyl]-1H-pyrrole-1-heptanoic acid and a pharmaceutically acceptable carrier..Iaddend. .Iadd.14. A method of inhibiting cholesterol synthesis in a human suffering from hypercholesterolemia comprising administering to said human the hemicalcium salt of [R-(R*,R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)- -3-phenyl-4-[(phenylamino)-carbonyl]-1H-pyrrole-1-heptanoic acid in unit dosage form..Iaddend.